Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer

被引：8
|
作者：
Geuijen, Cecile
Rovers, Eric
Nijhuis, Roy
den Blanken-Smit, Renate
Visser, Therese
Bartelink, Willem
Kramer, Arjen
Zondag-van der Zande, Vanessa
Clements, Carina
Kaldenberg, Linda
Nieuwenhuizen, Nellie
van Loo, Pieter Fokko
Roovers, Rob
Gallenne, Tristan
Price, Leo
Shamsili, Setareh Van Driel
Bakker, Lex
Logtenberg, Ton
de Kruif, John
Throsby, Mark
机构：
[1] Merus, Utrecht, Netherlands
[2] OcellO, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
560
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A bispecific single-chain Fv molecule targeting HER2 and HER3 exhibits tumor-targeting specificity in vivo and a therapeutic effect in vitro.
    Robinson, MK
    Russeva, M
    Horak, EM
    Heitner, T
    Simmons, HH
    Shaller, CC
    Reid, M
    Hodge, K
    Garrison, J
    Tesfaye, A
    Marks, JD
    Weiner, LM
    Adams, GP
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8983S - 8983S
  • [32] Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling
    Wong, Tai W.
    Lee, Francis Y.
    Yu, Chiang
    Luo, Feng R.
    Oppenheimer, Simone
    Zhang, Hongjian
    Smykla, Richard A.
    Mastalerz, Harold
    Fink, Brian E.
    Hunt, John T.
    Gavai, Ashvinikumar V.
    Vite, Gregory D.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 6186 - 6193
  • [33] Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3
    Clarke, N.
    Hopson, C.
    Hahn, A.
    Sully, K.
    Germaschewski, F.
    Yates, J.
    Akinseye, C.
    Mangatt, B.
    Jonak, Z.
    Matheny, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 98 - 99
  • [34] Targeting EGFR & HER2 & HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Antitumor Activity in HER2 Expressing Breast Cancer
    Liu, Hong Yan
    MOLECULAR THERAPY, 2018, 26 (05) : 147 - 147
  • [35] Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Schram, A.
    Macarulla, T.
    Cleary, J.
    Neuzillet, C.
    Arnold, D.
    Reiss, K. A.
    Bekaii-Saab, T.
    Rodon, J.
    Goto, K.
    Rha, S. Y.
    Duruisseaux, M.
    Leighl, N.
    Weinberg, B. A.
    Al-Hallak, M. N.
    Joe, A. K.
    Adeyemi, S.
    Wasserman, E.
    Koeman, K-J.
    Drilon, A.
    O'Reilly, E. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S895 - S896
  • [36] Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
    Koyama, Kumiko
    Ishikawa, Hirokazu
    Abe, Manabu
    Shiose, Yoshinobu
    Ueno, Suguru
    Qiu, Yang
    Nakamaru, Kenji
    Murakami, Masato
    PLOS ONE, 2022, 17 (05):
  • [37] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [38] A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
    Richards, Donald A.
    Braiteh, Fadi S.
    Garcia, A. A.
    Denlinger, Crystal Shereen
    Conkling, Paul R.
    Edenfield, William Jeffery
    Anthony, Stephen Patrick
    Hellerstedt, Beth A.
    Raju, Robert N.
    Becerra, Carlos
    Harb, Wael A.
    Smith, David A.
    McDonagh, Charlotte Fenton
    Kawash, Kate-Lyn
    Frye, Sasha
    Moyo, Victor M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
    Chen, Yi-Li
    Cui, Yue
    Liu, Xinyuan
    Liu, Guojian
    Dong, Xingchen
    Tang, Lei
    Hung, Yifeng
    Wang, Chunhe
    Feng, Mei-Qing
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 297 (06)
  • [40] Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade (vol 33, 922.e1, 2018)
    Geuijen, Cecile A. W.
    De Nardis, Camilla
    Maussang, David
    Rovers, Eric
    Gallenne, Tristan
    Hendriks, Linda J. A.
    Visser, Therese
    Nijhuis, Roy
    Logtenberg, Ton
    de Kruif, John
    Gros, Piet
    Throsby, Mark
    CANCER CELL, 2021, 39 (08) : 1163 - 1164
12345